Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 8/20 | 0.41 |
| ▸ | CCR3 | P51677 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL467873 | 1.00 | PTPRB (0.41) | PTPRBCCR3SMN1; SMN2LOXL2HDAC1 | |
| Bromide SCHEMBL19502581 | 0.99 | PTPRB (0.40) | PTPRBCCR3SMN1; SMN2LOXL2HDAC1 | |
| Bromide SCHEMBL467881 | 0.99 | PTPRB (0.40) | PTPRBCCR3SMN1; SMN2LOXL2HDAC1 | |
| SCHEMBL16573541 | 0.86 | CCR3 (0.40) | PTPRBCCR3SMN1; SMN2HDAC1HDAC6 | |
| Bromide SCHEMBL30476781 | 0.84 | MAPT (0.38) | PTPRBCCR3SMN1; SMN2LOXL2HDAC1 | |
| SCHEMBL1709764 | 0.83 | CCR3 (0.46) | PTPRBCCR3 | |
| SCHEMBL13184920 | 0.82 | PTPRB (0.48) | PTPRBCCR3 | |
| SCHEMBL17066116 | 0.81 | PTPRB (0.42) | PTPRB | |
| SCHEMBL16933159 | 0.78 | MEN1 (0.52) | PTPRBSMN1; SMN2RAB9AMAPTMEN1 | |
| SCHEMBL679480 | 0.78 | MEN1 (0.52) | PTPRBSMN1; SMN2RAB9AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12152023-B2 | Compositions, formulations and methods for treating ocular diseases | EyePoint Pharmaceuticals, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| EP-4101297-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Pharmaceuticals, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220274976-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint, Inc. | 2022-09-01 | — | — | US | disclosed |
| CN-114939117-A | Method of treating vascular leak syndrome | 视点制药公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2020-11-19 | — | — | US | disclosed |
| EP-3607821-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Therapeutics, Inc. (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-2967066-B1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | AERPIO THERAPEUTICS INC (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20180251457-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-09-06 | — | — | US | disclosed |
| US-20180237431-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-08-23 | — | — | US | disclosed |
| US-20180237430-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2018-08-23 | — | — | US | disclosed |
| US-20160220541-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2016-08-04 | — | — | US | disclosed |
| EP-2967066-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Therapeutics Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014145068-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | AERPIO THERAPEUTICS INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| CN-101506183-B | human protein tyrosine phosphatase inhibitors and methods of use thereof | PROCTER & GAMBLE | 2012-08-08 | — | — | CN | disclosed |
| EP-2451279-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | Akebia Therapeutics Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2385763-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | Akebia Therapeutics Inc. (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110253725-A1 | MULTI-PORT BEVERAGE AND FOOD CONTAINERS | KILLIAN WILLIAM | 2011-10-20 | — | — | US | disclosed |
| WO-2011005330-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | AKEBIA THERAPEUTICS INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010081172-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | AKEBIA THERAPEUTICS INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| CN-101506183-A | Human protein tyrosine phosphatase inhibitors and methods of use thereof | PROCTER & GAMBLE (US) | 2009-08-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220541-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPRB 609/4885CCR3 3589/4885SMN1; SMN2 3732/4885 |
| US-20180237431-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPRB 609/4885CCR3 3589/4885SMN1; SMN2 3732/4885 |
| US-20180237430-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPRB 609/4885CCR3 3589/4885SMN1; SMN2 3732/4885 |
| US-20180251457-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPRB 609/4885CCR3 3589/4885SMN1; SMN2 3732/4885 |
| US-20220274976-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPRB 609/4885CCR3 3589/4885SMN1; SMN2 3732/4885 |
| US-12152023-B2 | Compositions, formulations and methods for treating ocular diseases | TIE1, TEK, KDR | PTPRB 609/4885CCR3 3589/4885SMN1; SMN2 3732/4885 |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | PTPRB 609/4885CCR3 3589/4885SMN1; SMN2 3732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.